Treatment options for severe lupus nephritis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Landmark trials conducted by the National Institutes of Health established cyclophosphamide as the mainstay of therapy. Since then, the prognosis of patients with lupus nephritis has markedly improved, and 10-year survival rates now surpass 75%. These superior outcomes have come at the expense of adverse events such as serious infections and gonadal failure in a significant number of patients, and the relapsing nature of the disease continues to pose a problem. For these reasons, new treatment protocols, such as mycophenolate mofetil induction or sequential therapies using azathioprine or mycophenolate mofetil in the maintenance phase, have been developed in recent years with the goal to maintain remission and reduce adverse events. In addition, ongoing research into the pathogenesis of lupus nephritis has confirmed the importance of B and T cell activation, leading to the identification of potential new therapeutic targets. This article discusses established and novel treatment options for patients with severe lupus nephritis corresponding to WHO classes III, IV, and V with III or V with IV.

Original languageEnglish
Pages (from-to)356-365
Number of pages10
JournalArchivum Immunologiae et Therapiae Experimentalis
Volume52
Issue number5
StatePublished - Sep 1 2004

Fingerprint

Lupus Nephritis
Mycophenolic Acid
Azathioprine
National Institutes of Health (U.S.)
Therapeutics
Clinical Protocols
Systemic Lupus Erythematosus
Cyclophosphamide
B-Lymphocytes
Survival Rate
Maintenance
Morbidity
T-Lymphocytes
Kidney
Mortality
Infection
Research

Keywords

  • Drug therapy
  • Lupus erythematosus
  • Lupus nephritis
  • Systemic

ASJC Scopus subject areas

  • Immunology

Cite this

Treatment options for severe lupus nephritis. / Lenz, Oliver; Contreras, Gabriel.

In: Archivum Immunologiae et Therapiae Experimentalis, Vol. 52, No. 5, 01.09.2004, p. 356-365.

Research output: Contribution to journalArticle

@article{62ad78e4602646e8810ef9d2b70573a1,
title = "Treatment options for severe lupus nephritis",
abstract = "Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Landmark trials conducted by the National Institutes of Health established cyclophosphamide as the mainstay of therapy. Since then, the prognosis of patients with lupus nephritis has markedly improved, and 10-year survival rates now surpass 75{\%}. These superior outcomes have come at the expense of adverse events such as serious infections and gonadal failure in a significant number of patients, and the relapsing nature of the disease continues to pose a problem. For these reasons, new treatment protocols, such as mycophenolate mofetil induction or sequential therapies using azathioprine or mycophenolate mofetil in the maintenance phase, have been developed in recent years with the goal to maintain remission and reduce adverse events. In addition, ongoing research into the pathogenesis of lupus nephritis has confirmed the importance of B and T cell activation, leading to the identification of potential new therapeutic targets. This article discusses established and novel treatment options for patients with severe lupus nephritis corresponding to WHO classes III, IV, and V with III or V with IV.",
keywords = "Drug therapy, Lupus erythematosus, Lupus nephritis, Systemic",
author = "Oliver Lenz and Gabriel Contreras",
year = "2004",
month = "9",
day = "1",
language = "English",
volume = "52",
pages = "356--365",
journal = "Archivum Immunologiae et Therapiae Experimentalis",
issn = "0004-069X",
publisher = "Birkhauser Verlag Basel",
number = "5",

}

TY - JOUR

T1 - Treatment options for severe lupus nephritis

AU - Lenz, Oliver

AU - Contreras, Gabriel

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Landmark trials conducted by the National Institutes of Health established cyclophosphamide as the mainstay of therapy. Since then, the prognosis of patients with lupus nephritis has markedly improved, and 10-year survival rates now surpass 75%. These superior outcomes have come at the expense of adverse events such as serious infections and gonadal failure in a significant number of patients, and the relapsing nature of the disease continues to pose a problem. For these reasons, new treatment protocols, such as mycophenolate mofetil induction or sequential therapies using azathioprine or mycophenolate mofetil in the maintenance phase, have been developed in recent years with the goal to maintain remission and reduce adverse events. In addition, ongoing research into the pathogenesis of lupus nephritis has confirmed the importance of B and T cell activation, leading to the identification of potential new therapeutic targets. This article discusses established and novel treatment options for patients with severe lupus nephritis corresponding to WHO classes III, IV, and V with III or V with IV.

AB - Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Landmark trials conducted by the National Institutes of Health established cyclophosphamide as the mainstay of therapy. Since then, the prognosis of patients with lupus nephritis has markedly improved, and 10-year survival rates now surpass 75%. These superior outcomes have come at the expense of adverse events such as serious infections and gonadal failure in a significant number of patients, and the relapsing nature of the disease continues to pose a problem. For these reasons, new treatment protocols, such as mycophenolate mofetil induction or sequential therapies using azathioprine or mycophenolate mofetil in the maintenance phase, have been developed in recent years with the goal to maintain remission and reduce adverse events. In addition, ongoing research into the pathogenesis of lupus nephritis has confirmed the importance of B and T cell activation, leading to the identification of potential new therapeutic targets. This article discusses established and novel treatment options for patients with severe lupus nephritis corresponding to WHO classes III, IV, and V with III or V with IV.

KW - Drug therapy

KW - Lupus erythematosus

KW - Lupus nephritis

KW - Systemic

UR - http://www.scopus.com/inward/record.url?scp=10344229949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344229949&partnerID=8YFLogxK

M3 - Article

C2 - 15507877

AN - SCOPUS:10344229949

VL - 52

SP - 356

EP - 365

JO - Archivum Immunologiae et Therapiae Experimentalis

JF - Archivum Immunologiae et Therapiae Experimentalis

SN - 0004-069X

IS - 5

ER -